A pharmaceutical importer in India may have everything commercially ready – the overseas manufacturer is finalised, pricing is negotiated, distributors are waiting, and the first shipment is almost ready for dispatch.
Then the regulatory team checks the import documentation and discovers that the foreign manufacturing site is not covered under the required CDSCO Registration Certificate. In another case, the manufacturer may already hold Form 41, but the Indian importer has not completed the Form 10 import licence process. Sometimes the company reaches the filing stage only to discover that one of the products may fall under the new drug framework.
At that point, the problem is no longer logistics. It becomes a regulatory dependency that can delay the India launch.
This is why pharmaceutical import compliance should be planned before shipment dates are fixed.
For the normal commercial import of bulk drugs, APIs and finished pharmaceutical formulations into India, the regulatory process generally involves registration of the overseas manufacturing site and product, followed by the applicable CDSCO drug import licence.
For many pharmaceutical companies, the practical sequence is:
Product classification -> Applicant eligibility -> Form 40 -> Form 41 -> Form 8 or Form 8A -> Form 10 or Form 10A -> Commercial import
Understanding this sequence at the beginning can prevent avoidable document gaps, incorrect filings and repeated regulatory queries.
The Central Drugs Standard Control Organisation, commonly known as CDSCO, regulates the import of pharmaceutical drugs into India under the applicable provisions of the Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945.
A pharmaceutical company planning to import a drug commercially may need more than one regulatory approval.
The process generally has 2 important stages.
The first stage concerns registration of the overseas manufacturing premises and the drug proposed to be imported. This is generally handled through Form 40 and the Registration Certificate issued in Form 41.
The second stage is the commercial import licence.
For drugs other than Schedule X drugs:
Form 8 -> Form 10
For Schedule X drugs:
Form 8A -> Form 10A
Form 9 is also an important part of the import licence application framework.
This distinction matters because Form 41 and Form 10 perform different regulatory functions. A company should not treat a Registration Certificate as the final commercial import licence.
One of the most common sources of confusion among new pharmaceutical importers is the difference between CDSCO registration and the drug import licence.
Form 41 primarily relates to registration of the foreign manufacturing premises and the specified drugs.
Form 10 is the licence that allows the eligible importer to commercially import the approved drug into India.
The approval structure can therefore be understood in 2 stages.
The foreign manufacturing site and relevant pharmaceutical products are registered with CDSCO.
The application is generally prepared through Form 40.
After regulatory review and approval, the Registration Certificate is issued in Form 41.
Once the appropriate registration exists, the eligible Indian applicant proceeds with the commercial import licence application.
For normal non-Schedule X drugs, Form 8 is used and the resulting licence is Form 10.
For Schedule X drugs, Form 8A is used and the corresponding licence is Form 10A.
This sequence should be checked product by product and manufacturing site by manufacturing site.
A Registration Certificate for one overseas factory should not automatically be assumed to cover another manufacturing location.
Similarly, the inclusion of one formulation does not automatically mean every product marketed by the same company is covered.
This article is primarily relevant to companies planning commercial import of pharmaceutical drugs into India.
Typical applicants and stakeholders include:
The first regulatory question should not be “Which form do we fill?”
It should be:
What exactly are we importing and under which regulatory category does it fall?
That classification determines the correct approval path.
The CDSCO drug import framework discussed here can apply to pharmaceutical products such as bulk drugs, active pharmaceutical ingredients and finished formulations.
However, not every health-related product follows the same CDSCO process.
A company should first confirm whether the proposed product is actually regulated as a pharmaceutical drug.
Different regulatory routes may apply to:
Selecting the wrong CDSCO category at the beginning can lead to unnecessary documentation and delays.
Classification should therefore happen before preparing Form 40, Form 8 or any detailed dossier.
Another important step is determining whether the pharmaceutical product falls within the new drug framework.
This assessment should be completed early.
A company should check the regulatory position of the proposed drug, including its formulation, strength, dosage form, indication and other relevant product characteristics.
A pharmaceutical company should ideally confirm at least 4 points before proceeding:
If a new drug approval is required, simply preparing Form 40 and Form 10 documentation may not be sufficient.
This is why a regulatory assessment before filing is more useful than discovering the problem after CDSCO raises a query.
Before filing an application, the pharmaceutical company should conduct a basic readiness review.
Confirm whether the product is a pharmaceutical drug, medical device, cosmetic or another regulated category.
Determine whether the application relates to an API, bulk drug or finished formulation.
Check whether the product falls under Schedule X because the application route changes.
Determine whether additional regulatory approval is required.
Confirm that the Indian entity has the appropriate regulatory standing and licence required for the proposed application structure.
The legal name and full address of the overseas factory should remain consistent throughout the dossier.
The Power of Attorney should correctly identify the manufacturer, manufacturing site, Indian authorised agent and products.
Check the validity and applicability of documents such as the manufacturing licence, GMP certificate, COPP and Free Sale Certificate where applicable.
Specifications, analytical methods, stability information, manufacturing details and labels should correspond with the product being registered.
Before submission, compare every important product and company detail across the complete dossier.
A pre-filing consistency review can often identify issues before they become formal regulatory deficiencies.
There is no single document checklist that fits every pharmaceutical product.
The exact dossier depends on the product, overseas manufacturing location, applicant structure and regulatory status.
However, documentation generally comes from 2 major parties.
The overseas manufacturer may need to provide documents and technical information such as:
The documents should not simply be collected individually. They should also be cross-checked against one another.
For example, the manufacturing site written on the GMP certificate should correspond with the site included in the Power of Attorney and the CDSCO application.
The Indian importer or authorised agent may need to prepare documentation such as:
Preparing these documents is only one part of the process.
The more important task is ensuring that the foreign manufacturer’s documents and Indian applicant’s documents tell the same regulatory story.
A simple responsibility structure can prevent confusion during preparation.
| Requirement | Foreign Manufacturer | Indian Applicant |
|---|---|---|
| Foreign manufacturing licence | Primary responsibility | Verification |
| GMP, COPP and FSC | Primary responsibility | Verification |
| Technical product dossier | Primary responsibility | Review |
| Stability and specifications | Primary responsibility | Review |
| Power of Attorney | Joint | Joint |
| Indian drug licence | Not applicable | Primary responsibility |
| Form 40 information | Joint | Filing |
| Form 8 or Form 8A | Supporting information | Primary responsibility |
| Form 9 | Joint where applicable | Filing |
| Government fee | Supporting coordination | Primary responsibility |
| SUGAM submission | Supporting role | Primary responsibility |
| CDSCO query response | Joint | Coordination |
For companies working with overseas manufacturers, it is useful to create one master data sheet containing the approved manufacturer name, plant address, product name, dosage form, strength and regulatory documents.
This is a practical document-control tool, not an additional CDSCO form.
Determine whether the product falls under the pharmaceutical drug import route.
Also confirm whether it is:
Incorrect classification at this stage can affect the complete application.
Determine who will act as the Indian applicant or authorised agent.
The applicant’s existing drug licence and legal status should be checked before preparing the filing.
The Power of Attorney should correctly cover the overseas manufacturer, manufacturing site, relevant products and Indian authorised agent.
Do not wait until the final submission to check this document.
Form 40 is used for the foreign manufacturing site and drug registration process.
The application should be supported with the required administrative, technical and regulatory documentation.
A manufacturer registering 5 products requires a more detailed product-wise review than a company registering only 1 formulation.
The application is filed through the CDSCO online regulatory system.
All important information should be reviewed before the final submission because correcting inconsistent information later can require additional regulatory communication.
CDSCO may seek clarification or additional documentation during review.
A response should address every observation separately.
Instead of uploading a large bundle of replacement documents without explanation, the applicant should clearly map each CDSCO observation to the relevant clarification or revised document.
Once the Registration Certificate is issued, verify it carefully.
Check:
Do not assume the certificate is correct simply because it has been issued.
The next stage is the commercial import licence.
For non-Schedule X drugs:
Form 8 -> Form 10
For Schedule X drugs:
Form 8A -> Form 10A
The applicable supporting documents, including Form 9 and the Registration Certificate, should be prepared together.
After regulatory approval, the corresponding import licence allows commercial import within the approved regulatory scope.
The importer should ensure that the shipment matches the approved product and manufacturing site.
CDSCO compliance does not end after the first shipment.
The company should continue monitoring:
Government fees should always be shown separately from consultancy fees.
For foreign manufacturing premises registration, the current fee structure includes:
For example, suppose one foreign manufacturer wants to register 3 pharmaceutical drugs from one manufacturing site.
The basic calculation would be:
Manufacturing premises – USD 10,000
First drug – USD 5,000
Additional 2 drugs – USD 10,000
Total basic registration fee – USD 25,000
This example excludes inspection, laboratory testing and professional consultancy costs.
For the drug import licence stage, the applicable government fee structure includes:
Consultancy charges are separate and can depend on the number of products, manufacturing sites, dossier complexity, existing approvals and the extent of regulatory support required.
Pharmaceutical companies should be careful with websites that promise a fixed approval period.
For Registration Certificate applications, the regulatory framework provides a period of up to 9 months for processing a complete application, with an exceptional extension of up to 3 additional months under the prescribed circumstances.
This should not be interpreted as a guaranteed 9-month processing time for every application.
An application may be affected by:
For commercial planning, companies should work backwards from the proposed Indian market launch rather than waiting until the first shipment is ready.
The Registration Certificate framework includes a 3-year validity period.
Re-registration planning should begin well before expiry. The current regulatory approach recommends beginning the re-registration process around 9 months before the Registration Certificate expires.
The commercial import licence and Registration Certificate should be managed as connected approvals.
A company should maintain a regulatory calendar instead of relying on individual employees to remember expiry dates.
A simple compliance tracker should contain:
Many application problems are not caused by one missing certificate. They arise because the complete dossier is inconsistent.
Common pre-filing risk areas include:
Different versions of the factory address appear across the manufacturing licence, GMP certificate, Power of Attorney and application.
The document may list 4 products when the company intends to register 5.
The Indian entity may not hold the appropriate licence for the proposed application structure.
The company prepares the standard import registration dossier before verifying whether separate new drug approval is required.
The proposed label does not correspond with the product information submitted to CDSCO.
The Registration Certificate exists, but the intended product or manufacturing site is not actually covered.
A GMP certificate, manufacturing licence, COPP or other supporting regulatory document expires during preparation.
These issues are easier to correct before filing than after a formal regulatory query.
Consider an Indian pharmaceutical company planning to import 3 finished formulations from an overseas manufacturer.
Commercial agreements have been completed and the distributor wants to launch all 3 products together.
During the pre-filing regulatory review, the team identifies 3 gaps.
First, the manufacturer’s plant address appears differently on the GMP certificate and manufacturing licence.
Second, the Power of Attorney includes only 2 of the 3 products.
Third, the regulatory status of the third formulation indicates that a separate new drug assessment may be necessary.
Instead of immediately submitting the application, the company first corrects the manufacturer address documentation, revises the Power of Attorney and confirms the regulatory route for the third product.
After these points are resolved, the Form 40 dossier is prepared.
Once the correct Form 41 coverage is obtained, the company proceeds with the applicable Form 8 and Form 10 process.
This is an illustrative case study, but it demonstrates an important lesson.
A 2-week pre-filing document review can be more valuable than filing an incomplete application simply to save a few days at the beginning.
A CDSCO consultant cannot guarantee regulatory approval.
The consultant’s useful role is to make the application more complete, consistent and regulator-ready before submission.
Green Permits can support pharmaceutical companies with:
The objective should be to identify document gaps before they become CDSCO observations.
Before filing, confirm that:
Importing pharmaceutical drugs into India is not simply a customs or logistics exercise. The regulatory pathway begins much earlier.
For most commercial drug import projects, the company first needs to understand whether the overseas manufacturing premises and drug require registration through Form 40 and Form 41, followed by the applicable Form 8, Form 8A, Form 10 or Form 10A route.
The most important step is not filling the form quickly. It is ensuring that the product, manufacturing site, applicant, foreign regulatory documents and technical dossier are aligned before the application is submitted.
A pharmaceutical company planning to enter the Indian market should ideally complete its regulatory assessment before finalising shipment and launch dates. This gives the team enough time to resolve new drug questions, document inconsistencies, foreign manufacturer dependencies and CDSCO queries without disrupting commercial plans.
For businesses that need assistance with CDSCO drug import licence applications, Form 41 registration, Form 10 applications or pharmaceutical import compliance, Green Permits can support the documentation and regulatory filing process.
📞 +91 78350 06182
📧 wecare@greenpermits.in
👉 Book a Consultation with Green Permits
